ZOFRAN ODT
LOE ApproachingNDAORALTABLET, ORALLY DISINTEGRATING
Approved
Jan 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZOFRAN ODT (ondansetron) is an orally disintegrating tablet formulation of a selective serotonin 5-HT3 receptor antagonist used to prevent nausea and vomiting in multiple clinical settings. It is indicated for postoperative nausea/vomiting, chemotherapy-induced nausea/vomiting, and nausea/vomiting associated with endoscopic procedures. The drug works by blocking serotonin signaling in the chemoreceptor trigger zone and GI tract.
LOE Approaching
Product is in late-stage lifecycle with LOE approaching, signaling potential team contraction and transition to generic defense strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ZOFRAN ODT offers limited career growth potential given its LOE-approaching lifecycle stage and mature market positioning. Roles on this team are primarily defensive—focused on generic mitigation, payer negotiations, and market share retention rather than growth or innovation.
Brand ManagerMedical Science Liaison
Worked on ZOFRAN ODT at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.